Adicet Bio, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2020-10-13: Study NCT04584710; Company role Lead sponsor; Phase Phase 2; Status Active not recruiting.
- 2020-07-11: Study NCT04409327; Company role Lead sponsor; Phase Phase 2; Status Terminated.
- 2019-10-21: Study NCT04139915; Company role Lead sponsor; Phase Phase 3; Status Withdrawn.
- 2019-04-15: Study NCT04668352; Company role Lead sponsor; Phase Phase 3; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2020-10-13 | NCT04584710 A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults | Lead sponsor | Phase 2 | Active not recruiting | Covid19 | 60 | 2021-02 |
| 2020-07-11 | NCT04409327 Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes | Lead sponsor | Phase 2 | Terminated | COVID19 | 36 | 2021-01-24 |
| 2019-10-21 | NCT04139915 Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly | Lead sponsor | Phase 3 | Withdrawn | Clinically Symptomatic Respiratory Illness | 0 | 2019-11-15 |
| 2019-04-15 | NCT04668352 A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly | Lead sponsor | Phase 3 | Completed Results posted | Respiratory Tract Infections | 1,024 | 2019-12-02 |
| 2017-11-15 | NCT03373903 Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the Elderly | Lead sponsor | Phase 2 | Active not recruiting | Respiratory Tract Infections | 652 | 2018-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |